Litcius/Paper detail

A Distinct Cytokine Profile and Stromal Vascular Fraction Metabolic Status without Significant Changes in the Lipid Composition Characterizes Lipedema

Stefan Wolf, Jeremy Deuel, Maija Hollmén, Gunther Felmerer, Bong‐Sung Kim, Mauro Vasella, Lisanne Grünherz, Pietro Giovanoli, Nicole Lindenblatt, Epameinondas Gousopoulos

2021International Journal of Molecular Sciences44 citationsDOIOpen Access PDF

Abstract

Lipedema is an adipose tissue disorder characterized by the disproportionate increase of subcutaneous fat tissue in the lower and/or upper extremities. The underlying pathomechanism remains unclear and no molecular biomarkers to distinguish the disease exist, leading to a large number of undiagnosed and misdiagnosed patients. To unravel the distinct molecular characteristic of lipedema we performed lipidomic analysis of the adipose tissue and serum of lipedema versus anatomically- and body mass index (BMI)-matched control patients. Both tissue groups showed no significant changes regarding lipid composition. As hyperplastic adipose tissue represents low-grade inflammation, the potential systemic effects on circulating cytokines were evaluated in lipedema and control patients using the Multiplex immunoassay system. Interestingly, increased systemic levels of interleukin 11 (p = 0.03), interleukin 28A (p = 0.04) and interleukin 29 (p = 0.04) were observed. As cytokines can influence metabolic activity, the metabolic phenotype of the stromal vascular fraction was examined, revealing significantly increased mitochondrial respiration in lipedema. In conclusion, despite sharing a comparable lipid profile with healthy adipose tissue, lipedema is characterized by a distinct systemic cytokine profile and metabolic activity of the stromal vascular fraction.

Topics & Concepts

Adipose tissueStromal vascular fractionMedicineInternal medicineCytokineEndocrinologyStromal cellPathologySystemic inflammationInflammationInterleukin 6Lymphatic System and DiseasesSkin and Cellular Biology ResearchPI3K/AKT/mTOR signaling in cancer